Objective To explore the relationship between emotional state,metacognition,and serum levels of miRNA-134 and miRNA-16 with disease fear in patients with depression.Methods A total of 142 patients with first-episode,medication-free depression treated at Shaoxing Seventh People's Hospital from September 2022 to January 2024 were se-lected.According to the fear of progression questionnaire-short form(FoP-Q-SF)score,the patients were divided into a high fear group(79 cases)and a low fear group(63 cases).The baseline data,emotional state,metacognition,and ser-um levels of miRNA-134 and miRNA-16 were compared between the two groups.Logistic regression analysis was used to evaluate the factors affecting the fear of disease in patients with depression.Results The scores of Hamilton depression scale-17(HAMD-17),Hamilton anxiety scale-14(HAMA-14),and the metacognitions questionnaire-30(MCQ-30)in the high fear group were significantly higher than those in the low fear group(P＜0.05).The serum levels of miRNA-134 and miRNA-16 were significantly lower than those in the low fear group(P＜0.05).Additionally,there were significant differences in gender,age,employment status,living alone,family history of depression,and sleep duration between the two groups(P＜0.05).Logistic regression analysis identified living alone,MCQ-30 score,serum levels of miRNA-134 and miRNA-16 as significant factors affecting disease fear,with OR values of 8.149,1.094,＜0.001,and＜0.001,re-spectively.Conclusion Metacognition levels and serum expression of miRNA-134 and miRNA-16 significantly impact the fear of disease in patients with depression.
维普
万方数据
